Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice

Zhou, Feng; Zhang, Ying; Chen, Jing; Hu, Xuemei; Xu, Yancheng

doi:10.1016/j.ejphar.2016.10.016

Cited by 66 publications

(50 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ALI occurs as a result of the loss of integrity of capillary endothelial cells and alveolar epithelial cells due to various harmful agents, leading to diffuse interstitial lung and alveolar edema . Decreased lung volume, pulmonary compliance, and ventilation/blood imbalances are observed during ALI, which can trigger progressive hypoxia and respiratory distress .…”

Section: Discussionmentioning

confidence: 99%

Alkannin attenuates lipopolysaccharide‐induced lung injury in mice via Rho/ROCK/NF‐κB pathway

Lin

Hou

et al. 2019

J Biochem & Molecular Tox

View full text Add to dashboard Cite

We investigated the effects and associated mechanism of alkannin (AL) on lipopolysaccharide (LPS)-induced acute lung injury in a mouse model. Pretreatment with AL in vivo significantly reduced the lung wet/dry weight ratio and inhibited lung myeloperoxidase activity and malondialdehyde content, while increasing superoxide dismutase activity. Hematoxylin and eosin staining demonstrated that AL attenuated lung histopathological changes. In addition, AL-inhibited overproduction of proinflammatory cytokines in bronchoalveolar lavage fluid and lung tissues in LPS-injured mice and LPS-exposed A549 cells. Further analysis showed that AL-inhibited induction of the Rho/ROCK/NF-κB pathway via LPS-induced inflammation in mice and A549 cells. Fasudil, a selective ROCK inhibitor, showed similar effects. Overall, the findings indicate that AL suppresses the expression of messenger RNAs and proteins associated with Rho/ROCK/NF-κB signaling to effectively ameliorate lung injury. K E Y W O R D S alkannin, lipopolysaccharide, lung injury, Rho/ROCK/NF-κB

show abstract

Section: Discussionmentioning

confidence: 99%

Alkannin attenuates lipopolysaccharide‐induced lung injury in mice via Rho/ROCK/NF‐κB pathway

Lin

Hou

et al. 2019

J Biochem & Molecular Tox

View full text Add to dashboard Cite

show abstract

“…2 and ▶3) [21]. While the benefits of DPP-4 inhibition are unproven, there is a clear anti-inflammatory and lung-protective effect of GLP-1 receptor analogues in obesity that may prove useful in mitigating risks for severe disease [71,125]. Furthermore, co-existing obesity hypoventilation syndrome and obstructive sleep apnea, both complications of obesity, may compromise respiratory function that could also account for the observed effects.…”

Section: Pathophysiology and Riskmentioning

confidence: 99%

Endocrine Conditions and COVID-19

et al. 2020

View full text Add to dashboard Cite

COVID-19 was declared a global pandemic by the WHO and has affected millions of patients around the world. COVID-19 disproportionately affects persons with endocrine conditions, thus putting them at an increased risk for severe disease. We discuss the mechanisms that place persons with endocrine conditions at an additional risk for severe COVID-19 and review the evidence. We also suggest precautions and management of endocrine conditions in the setting of global curfews being imposed and offer practical tips for uninterrupted endocrine care.

show abstract

“…While DPP-4 inhibition as a therapeutic target to reduce COVID-19 severity remains speculative, GLP-1 receptor analogues have been proven to be immunoregulatory and lung protective in animal models. 24…”

Section: Specific Immune Dysregulation Pathways Obesitymentioning

confidence: 99%

“…25 A disintegrin and metallopeptidase domain 17 (ADAM17), the enzymatic cleaver of ACE2, is lower in mouse models of diabetes mellitus, which may increase the risk of COVID-19 infection. 24,25 Co-existing complement deficits, impaired antigen presenting cell function, elevated TNF-α and IL-8, and compromised T-cell function all independently contribute to the dysregulated immune milieu of diabetes mellitus. [27][28][29] In addition, the co-existence of other risk factors including obesity and hypertension further amplifies the pre-existing immunological dysfunction in diabetes.…”

Section: Diabetes Mellitusmentioning

confidence: 99%